<DOC>
	<DOCNO>NCT02561130</DOCNO>
	<brief_summary>The purpose study determine whether patient early type 2 diabetes , short-term intensive metabolic intervention comprise Forxiga , metformin , basal insulin glargine lifestyle approach superior standard diabetes therapy achieve sustain diabetes remission .</brief_summary>
	<brief_title>Remission Evaluation Metabolic Intervention Type 2 Diabetes With Forxiga</brief_title>
	<detailed_description>This multicentre , open-label , randomize control trial 152 patient recently-diagnosed T2DM . Participants randomize 2 treatment group : ( ) 12-week course treatment Forxiga , metformin , insulin glargine lifestyle therapy , ( b ) standard diabetes therapy , follow total 64 week ( 1 year 3 month ) . In participant HbA1C &lt; 7.3 % 12 week visit , glucose-lowering medication discontinue participant encourage continue lifestyle modification regular glucose monitoring . Participants HbA1C ≥ 7.3 % visit experience hyperglycemia relapse stop drug receive standard glycemic management inform current Canadian Diabetes Association clinical practice guideline .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>1. men woman 3080 year age inclusive ; 2. type 2 diabetes mellitus diagnosed physician within 8 year prior patient enrollment ; 3. antidiabetic drug regimen ( either drug dose drug ) unchanged 8 week prior screen randomization ; 4 . HbA1C 6.59.5 % inclusive hypoglycemic agent HbA1C ≤ 8.0 % 2 glucoselowering agent ; 5. body mass index ≥ 23 kg/m2 ; 6. ability willingness perform selfmonitoring capillary blood glucose ( SMBG ) ; 7. ability willingness selfinject insulin ; 8. provision inform consent . 1. current use insulin therapy ; 2. history hypoglycemia unawareness , severe hypoglycemia require assistance ; 3. history endstage renal disease renal dysfunction evidence eGFR &lt; 60 mL/min/1.73 m2 MDRD formula ; 4. history lactic acidosis diabetic ketoacidosis ; 5. active liver disease elevate alanine transferase ( ALT ) level ≥ 2.5 time upper limit normal time enrollment ; 6. history bladder cancer undiagnosed hematuria ; 7. history breast cancer ; 8. history polycythemia ; 9. evidence volume depletion hypotension ( systolic blood pressure &lt; 90 mmHg ) ; 10. systolic blood pressure &gt; 180 mmHg diastolic blood pressure &gt; 105 mmHg ; 11. diagnose cardiovascular disease ( unless clear moderate intensity exercise program specialist ) include : 1. history acute coronary syndrome , hospitalization unstable angina , myocardial infarction , revascularization coronary artery bypass graft percutaneous coronary intervention ; 2. evidence coronary artery disease ; 3. peripheral vascular disease , valvular heart disease , cardiomyopathy , aortic dissection , tachyarrhythmias , bradyarrhythmias , prior stroke TIA ; 4. prior hospitalization heart failure ; 5 . ECG finding concern ischemic heart disease ( i.e . pathological Qwaves , STsegmentTwave abnormalities contiguous lead , leave anterior hemiblock , leave bundle branch block , second third degree atrioventricular block ) . 12. dependence oxygen ; 13. history disease require frequent intermittent continuous systemic glucocorticoid treatment ; 14. history bariatric surgery , plan bariatric surgery next 1.5 year ; 15. history major illness life expectancy &lt; 3 year ; 16. history injury condition significantly limit participant 's ability achieve moderate level physical activity ; 17. history excessive alcohol intake , acute chronic ; 18. currently pregnant , breastfeeding , use reliable method birth control duration trial female childbearing potential ; reliable method birth control include oral contraceptive ( birth control pill ) , hormonal injection , implant , patch , vaginal ring , intrauterine device , barrier method ( condom spermicide ) , tubal ligation , partner vasectomy abstinence ; 19. know hypersensitivity metformin , Forxiga , insulin glargine .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Insulin</keyword>
	<keyword>Glargine</keyword>
	<keyword>Metformin</keyword>
	<keyword>Forxiga</keyword>
	<keyword>Diet</keyword>
	<keyword>Exercise</keyword>
	<keyword>Lifestyle</keyword>
</DOC>